BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ratnasari N, Lestari P, Renovaldi D, Raditya Ningsih J, Qoriansas N, Wardana T, Hakim S, Signa Aini Gumilas N, Indrarti F, Triwikatmani C, Bayupurnama P, Setyo Heriyanto D, Astuti I, Mubarika Harjana S. Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients. PLoS One 2022;17:e0263298. [PMID: 35157721 DOI: 10.1371/journal.pone.0263298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Otmani K, Rouas R, Lewalle P. OncomiRs as noncoding RNAs having functions in cancer: Their role in immune suppression and clinical implications. Front Immunol 2022;13:913951. [DOI: 10.3389/fimmu.2022.913951] [Reference Citation Analysis]
2 Zelli V, Compagnoni C, Capelli R, Corrente A, Di Vito Nolfi M, Zazzeroni F, Alesse E, Tessitore A. Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: focus on hepatocellular carcinoma. Front Oncol 2022;12:940056. [DOI: 10.3389/fonc.2022.940056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 El-Mahdy HA, Sallam AM, Ismail A, Elkhawaga SY, Elrebehy MA, Doghish AS. miRNAs inspirations in hepatocellular carcinoma: Detrimental and favorable aspects of key performers. Pathol Res Pract 2022;233:153886. [PMID: 35405621 DOI: 10.1016/j.prp.2022.153886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]